OKYO Pharma Ltd
OKYO evidence brief
What we can confirm
- Market Cap:
- $73.5M
What it means
What to watch
Prepared research question
What matters most for OKYO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · OKYO
OKYO Pharma Ltd (OKYO) is a Guernsey-domiciled, NASDAQ-listed biopharmaceutical company developing urcosimod, a potential first-in-class treatment for neuropathic corneal pain (NCP), with no FDA-approved therapies currently available.
Key risk: Cash runway uncertainty
Market Cap
$73.5M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Tracking 2 clinical trials for OKYO Pharma Ltd.
OKYO Pharma Ltd (OKYO) is a Guernsey-domiciled, NASDAQ-listed biopharmaceutical company developing urcosimod, a potential first-in-class treatment for neuropathic corneal pain (NCP), with no FDA-approved therapies currently available.
- Lead program urcosimod is being developed as a potential first-in-class treatment for neuropathic corneal pain, a condition with no FDA-approved therapies [sec · filed 2026-07-20].
- As of March 31, 2026, cash and cash equivalents plus short-term investments were approximately $20.6 million, with a working capital surplus of approximately $12.3 million [sec · filed 2026-07-20].
- Net loss for the year ended March 31, 2026, was $8.9 million; accumulated deficit stood at $152 million (of which $109 million relates to a discontinued business prior to 2018) [sec · filed 2026-07-20].
- Appointed Flavio Mantelli, MD, PhD as Chief Medical Officer in February 2026; he previously led the clinical development and global launch of Oxervate® (cenegermin-bkbj) [sec · filed 2026-07-20].
- The company delisted from the London Stock Exchange in May 2023 and its principal trading market is now the NASDAQ Capital Market [sec · filed 2026-07-20].
What works
- Urcosimod targets a novel GPCR (CMKLR1/ChemR23) and addresses a high unmet medical need — neuropathic corneal pain — with no currently approved therapies [sec · filed 2026-07-20].
- The company has assembled an ophthalmology team with extensive experience, including a CMO who led a blockbuster orphan drug launch (Oxervate®) [sec · filed 2026-07-20].
- As of March 31, 2026, the company had $20.6 million in cash and equivalents, providing a near-term operational runway [sec · filed 2026-07-20].
What to weigh
- The company has a history of net losses and an accumulated deficit of $152 million as of March 31, 2026 [sec · filed 2026-07-20].
- The directors have stated that without raising additional funding, the company will not be able to initiate the next phase of trials and meet liabilities as they fall due within 12 months from the date of the 2025 financial statements [sec · filed 2025-07-18].
- All product candidates are in early-stage development; successful completion of one stage does not ensure success in subsequent stages [sec · filed 2026-07-20].
- Commercialization of urcosimod depends on successful further human trials and receipt of marketing approvals, which are uncertain [sec · filed 2026-07-20].
From the filings
Quoted directly from source documents.
Lead program urcosimod targets neuropathic corneal pain with no FDA-approved therapies
“Our lead program, urcosimod, is being developed as a potential first-in-class treatment for neuropathic corneal pain, a severe condition for which there are currently no FDA-approved therapies.”
SEC filings · July 20, 2026
Cash position as of March 31, 2026
“As of March 31, 2026, our cash and cash equivalents, plus cash classified as a short term investment balance was approximately $20.6 million and our working capital surplus was approximately $12.3 million.”
SEC filings · July 20, 2026
Appointment of Flavio Mantelli as CMO
“On February 10, 2026, we announced the appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer.”
SEC filings · July 20, 2026
Risks & what to watch (4)›
Key risks
- Cash runway uncertainty — Without additional funding, the company may not be able to initiate next-phase trials or meet liabilities within 12 months [sec · filed 2025-07-18].
- Clinical trial failure risk — All product candidates are early-stage; successful completion of one stage does not ensure later success [sec · filed 2026-07-20].
- Commercialization dependency — Urcosimod commercialization depends on successful trials and regulatory approvals, which are uncertain [sec · filed 2026-07-20].
- Historical accumulated losses — Accumulated deficit of $152 million as of March 31, 2026, with recurring net losses [sec · filed 2026-07-20].
What to watch
- Ability to raise additional capital to fund next-phase clinical trials for urcosimod [sec · filed 2026-07-20].
- Progress of urcosimod clinical trials in neuropathic corneal pain and other corneal/anterior segment diseases [sec · filed 2026-07-20].
- Regulatory milestones for urcosimod in the US and other jurisdictions [sec · filed 2026-07-20].
- Cash burn rate and whether the company can maintain operations beyond the current runway [sec · filed 2025-07-18].
Sources: SEC filings · Generated September 30, 2026 · How we verify sources →
Run OKYO Pharma Ltd through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available OKYO Pharma Ltd facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Short Interest
as of Apr 20, 2026- % of float
- 0.5%
- Days to cover
- 1.9
- Shares short
- 206,345
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
OKYO short interestFrequently asked questions
What is the AI investment thesis for OKYO Pharma Ltd?
OKYO Pharma Ltd (OKYO) is a Guernsey-domiciled, NASDAQ-listed biopharmaceutical company developing urcosimod, a potential first-in-class treatment for neuropathic corneal pain (NCP), with no FDA-approved therapies currently available.
Who is the CEO of OKYO Pharma Ltd?
Mr. Robert J. Dempsey M.B.A. is the chief executive officer of OKYO Pharma Ltd (OKYO).
Where is OKYO Pharma Ltd headquartered?
OKYO Pharma Ltd (OKYO) is headquartered in London, United Kingdom.
What therapeutic areas does OKYO Pharma Ltd focus on?
OKYO Pharma Ltd develops therapies across Oncology, Neurology, Ophthalmology, Pain.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.